Table 2.
Pembrolizumab plus chemotherapy cost-effectiveness at additional modelled price points
Parameter | Base case model analysis* | |
WTP value, $/QALY | 100 000 | 15 000 |
Nivolumab cost, $/mg | 12.05 | 31.38 |
Total cost, $ | 176 197 | 235 651 |
QALYs | 1.61 | 1.61 |
ICER, $/QALY | 99 915 | 149 907 |
*Only the cost of pembrolizumab was varied.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; WTP, Willingness-to-pay.